Cognizant, Google Cloud Expand AI Partnership

- This expanded alliance is part of a larger strategy that includes Cognizant's commitment to invest $1 billion in generative AI over three years and to train over 70,000 of its associates on Google Cloud's AI technologies, including the Gemini models. - The partnership's focus on "agentic AI" is particularly relevant to biopharma, where it is being applied to automate and accelerate drug development by creating semi-autonomous systems that can manage complex workflows in areas like clinical data flow, document generation, and regulatory submissions. - Cognizant will leverage Google Cloud's specific life science platforms, such as the Target and Lead Identification Suite and the Multiomics Suite, which are designed to accelerate in silico drug design and streamline the analysis of genomic data. - The collaboration builds on Cognizant's significant presence in the sector; the company's health sciences vertical is its largest, and it already serves 9 of the top 10 global biotech companies and all of the top global pharmaceutical firms. - This is one of several strategic AI initiatives for Cognizant in the life sciences space; the company is also collaborating with NVIDIA to use its BioNeMo platform to accelerate drug discovery, indicating a multi-platform approach to AI in R&D. - As part of the partnership, Cognizant is establishing Gemini Centers of Excellence and a Gemini Studio within its Cloud AI Innovation hubs to help enterprise clients, including those in biotech, architect and scale custom AI solutions. - In June 2024, the partnership launched its first suite of healthcare-specific large language model (LLM) solutions built on Google Cloud's technology, aimed at improving administrative processes and business outcomes in regulated healthcare environments.